Instruments Segment to Hold Significant Share of Transient Protein Expression Market During 2023-2031

According to our latest study on "Transient Protein Expression Market Forecast to 2031 - Global Analysis - Product Type, Application, End User, and Geography," the market was valued at US$ 836.68 million in 2023 and is projected to reach US$ 1,320.38 million by 2031; it is expected to register a CAGR of 5.9% from 2023 to 2031. The report highlights the key factors driving the transient protein expression market growth and prominent players with their developments in the market.

The transient protein expression market has been segmented on the basis of product type, application, and end user.

Based on product type, the transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2023. Instruments used in transient protein expression are categorized as automated transient protein expression systems and manual transient protein expression systems. The choice of instrument depends on the kind of protein, the requirements for functional activity, and the desired yield. In March 2022, ProteoGenix launched its XtenCHOTM transient expression system. This new proprietary mammalian cell-based expression host is designed to achieve up to 10 times more yields with less hands-on time compared to existing solutions, which can be ascribed to enhanced plasmid stability and optimized metabolism. The new CHO host aims to simplify recombinant protein production and speed up early-phase drug screening. The manual method entirely depends on the abilities and availability of accomplished cell culture scientists and technicians, among others. It is highly repetitive and requires a considerable time investment.

By application, the market is segmented into genomic research, gene therapy, bioproduction, cancer research, and drug development. The genomic research segment accounted for the largest share of the market in 2023. Large-scale transient gene expression (TGE) is a technology that is deemed suitable for producing recombinant therapeutic proteins. TGE involves producing a recombinant protein over 1-14 days following the transfer of DNA into single-cell suspension cultures. A recombinant gene is typically cloned in a nonviral expression vector and then transfected into cells using a chemical delivery agent such as calcium phosphate (CaPi). On the other hand, stable transfection results in high protein yield. After the recombinant DNA is transfected into animal cells, it can either be integrated (stable expression) into the host genome or maintained in episomal form (transient expression). In stable expression systems, the foreign gene is passed on to subsequent generations, and the expression is maintained from one generation to the next. On the other hand, transient expression is also termed as temporary expression as the foreign gene is not passed on to the next generations.

Genomics is the study of all the genes of a person (the genome), including their interactions with each other and with the environment of the individual. Objectives of genomic research include determining the function of genes and other genome elements; identifying differences in human DNA sequencing and their consequences; discovering the structure of 3-dimensional proteins; investigating the function of various protein structures; exploring interactions between DNA and proteins in vivo settings; comparing genome sequences of organisms; developing new technologies to improve genomics research and enhance DNA sequencing performance; and exploring ethical, legal, and social issues related to genomic research.

Based on end user, the transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment dominated the market in 2023. Cancer and infectious diseases are a few of the most common causes of death in the world. Many expression systems have been developed to aid in the production of pharmaceutical products. In recent years, efforts have been made to develop therapeutic proteins directed against infectious diseases and cancer by using plants as bioreactors. Recent advancements in plant-based (stable and transient) therapeutic protein expression along with a shift in focus toward the commercial production of vaccines, antibodies, and biopharmaceuticals leads to maximum use of therapeutic protein expression system in pharmaceutical and biotechnology companies. Besides, pharmaceutical and biotechnology firms are increasing their spending on research and R&D activities. Cell-free protein expression systems have been one of the most recent developments that have the potential to benefit the transient protein expression market over the forecast period.

Thermo Fisher Scientific, Promega Corporation, Merck KGAA, Takara Bio Inc, Qiagen, Bio-Rad Laboratories, Inc., New England Biolabs, Genscript Biotech Corporation, Agilent, Lonza, Mirus Bio LLC, and MaxCyte Inc are among the leading companies operating in the global transient protein expression market.

Companies operating in the transient protein expression market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the transient protein expression market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall transient protein expression market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

- Thermo Fisher Scientific to Acquired QIAGEN N.V. Benefits of the Transaction are Expands Specialty Diagnostics Portfolio with Attractive Molecular Diagnostics Capabilities, Including Infectious Disease Testing, Complementary Offering Enhances Unique Value Proposition for Life Sciences Customers, Commercial and Geographic Reach Expand Customer Access, Delivers Attractive Financial Benefits through the PPI Business System, Including Proven Integration Approach. (Source: Thermo Fisher Scientific Inc., Press Release, March 2020)

- Merck signed agreements licensing its CRISPR technology to two companies PanCELLa, a cell therapy firm, and Takara Bio USA, Inc., a biotechnology company. Licenses aim to accelerate drug discovery research leading to the development of new therapies, PanCELLa agreement marks Merck's first CRISPR license for bioproduction, Takara Bio USA agreement gives access to Merck's CRISPR integration and vector technologies for Takara's vector products and cell engineering services. (Source: Merck, Newsletter, October 2020).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com